STOCK TITAN

AVG Group Sarl Takes Strategic Investment in Alternus Energy Group PLC

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags

OSLO, Norway and LUXEMBOURG, April 16, 2021 /PRNewswire/ -- The Nordics continue to make a significant push into the renewable energy market and diversify away from their oil and gas history. AVG Group Sarl (AVG) a Luxembourg based asset manager, with a strategic focus in Nordic ESG and Impact investments has closed an approximate NOK 80,000,000 investment into Alternus Energy Group PLC (Alternus).

"We are delighted to have AVG as a new financing partner and look forward to working with them going forward as we continue to grow Alternus over the next few years in our continuing mission to become one of the largest pan-European solar operators by the end of the decade," Alternus Energy CEO Vincent Browne said in a statement.

AVG will also support Alternus as it grows in the coming years through both potential further financings and also by providing Nordic support to an Alternus Norwegian subsidiary, that will become a center of excellence within the group for technology supply Alternus solar projects. AVG will advise local Norwegian management on the latest solar technology available in Norway and also assist it in obtaining Nordic Government financial support through DFIs and various renewable energy financing programs.

"We look forward to providing support, engineering capabilities and innovation coming from Norway and the Nordics where possible," said CEO Karl Andersen.

Alternus has a current portfolio of 39 owned or contracted parks in Italy, Netherlands, Romania, Poland and Germany in excess of 140 MWp installed capacity. Alternus has recently announced a further 1.2GW of contracted projects for potential acquisition – subject to ongoing due diligence – that will see it grow by nearly ten times by the end of 2023.

About Alternus Energy Group Plc

Alternus Energy Group (NOTC: ALT) is a fast-growing pan-European independent power producer ("IPP"),  with a focus on the midsized utility solar PV market. Alternus owns and operates a diverse portfolio of utility scale solar PV parks that connect directly to national power grids on long-term government contracts ("FiT") and/or Power Purchase Agreements ("PPAs") with investment grade off-takers. Having started in 2016 with two parks and 6 MWp capacity, the current portfolio consists of 39 owned or contracted parks in Germany, Italy, Netherlands, Romania and Poland in excess of 140 MWp capacity. Alternus works closely with both local and international specialist development partners that each provide a constant pipeline of new projects for acquisition by Alternus. Alternus aims to own and operate over 2 GWs of solar parks by the end of 2025 and to become one of the largest pan-European IPPs by the end of the decade.

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/avg-group-sarl-takes-strategic-investment-in-alternus-energy-group-plc-301270818.html

SOURCE AV Group Sarl

Altimmune, Inc.

NASDAQ:ALT

ALT Rankings

ALT Latest News

ALT Stock Data

570.05M
70.33M
0.78%
62.24%
25.01%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
GAITHERSBURG

About ALT

altimmune, inc. is a clinical stage biotechnology company developing next-generation immunotherapeutics and vaccines to address significant public health and biodefense needs. by leveraging specific attributes of its two independent and complementary platform technologies, altimmune can rapidly design product candidates against a wide range of disease targets, including respiratory diseases, chronic infections, and cancer. our densigen™ t-cell platform technology is uniquely suited to direct the immune response against traditionally difficult disease targets, including chronic infections and cancer, by directing an individual’s immune system against multiple target antigens instead of just one. altimmune’s respirvec™ platform utilizes convenient needle-free intranasal delivery to achieve broad immunity against disease pathogens more rapidly than conventional vaccines. vaxin’s product candidates are easily manufactured, highly stable, and provide a safe, effective alternative to current